Recent advances in HIV-associated Kaposi sarcoma

Kaposi sarcoma (KS) is a mesenchymal tumour caused by KS-associated herpesvirus and is an AIDS-defining illness. Despite a decline in incidence since the introduction of combination anti-retroviral therapy, KS remains the most common cancer in people living with HIV in sub-Saharan Africa, where it c...

Descripción completa

Detalles Bibliográficos
Autores principales: Dalla Pria, Alessia, Pinato, David J., Bracchi, Margherita, Bower, Mark
Formato: Online Artículo Texto
Lenguaje:English
Publicado: F1000 Research Limited 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6600854/
https://www.ncbi.nlm.nih.gov/pubmed/31297181
http://dx.doi.org/10.12688/f1000research.17401.1
_version_ 1783431196417458176
author Dalla Pria, Alessia
Pinato, David J.
Bracchi, Margherita
Bower, Mark
author_facet Dalla Pria, Alessia
Pinato, David J.
Bracchi, Margherita
Bower, Mark
author_sort Dalla Pria, Alessia
collection PubMed
description Kaposi sarcoma (KS) is a mesenchymal tumour caused by KS-associated herpesvirus and is an AIDS-defining illness. Despite a decline in incidence since the introduction of combination anti-retroviral therapy, KS remains the most common cancer in people living with HIV in sub-Saharan Africa, where it causes significant morbidity and mortality. This review reflects on recent epidemiological data as well as current management, unmet needs and future perspectives in the treatment of HIV-associated KS with particular emphasis on the potential role of immune checkpoint inhibitors.
format Online
Article
Text
id pubmed-6600854
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher F1000 Research Limited
record_format MEDLINE/PubMed
spelling pubmed-66008542019-07-10 Recent advances in HIV-associated Kaposi sarcoma Dalla Pria, Alessia Pinato, David J. Bracchi, Margherita Bower, Mark F1000Res Review Kaposi sarcoma (KS) is a mesenchymal tumour caused by KS-associated herpesvirus and is an AIDS-defining illness. Despite a decline in incidence since the introduction of combination anti-retroviral therapy, KS remains the most common cancer in people living with HIV in sub-Saharan Africa, where it causes significant morbidity and mortality. This review reflects on recent epidemiological data as well as current management, unmet needs and future perspectives in the treatment of HIV-associated KS with particular emphasis on the potential role of immune checkpoint inhibitors. F1000 Research Limited 2019-06-26 /pmc/articles/PMC6600854/ /pubmed/31297181 http://dx.doi.org/10.12688/f1000research.17401.1 Text en Copyright: © 2019 Dalla Pria A et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Dalla Pria, Alessia
Pinato, David J.
Bracchi, Margherita
Bower, Mark
Recent advances in HIV-associated Kaposi sarcoma
title Recent advances in HIV-associated Kaposi sarcoma
title_full Recent advances in HIV-associated Kaposi sarcoma
title_fullStr Recent advances in HIV-associated Kaposi sarcoma
title_full_unstemmed Recent advances in HIV-associated Kaposi sarcoma
title_short Recent advances in HIV-associated Kaposi sarcoma
title_sort recent advances in hiv-associated kaposi sarcoma
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6600854/
https://www.ncbi.nlm.nih.gov/pubmed/31297181
http://dx.doi.org/10.12688/f1000research.17401.1
work_keys_str_mv AT dallapriaalessia recentadvancesinhivassociatedkaposisarcoma
AT pinatodavidj recentadvancesinhivassociatedkaposisarcoma
AT bracchimargherita recentadvancesinhivassociatedkaposisarcoma
AT bowermark recentadvancesinhivassociatedkaposisarcoma

Ejemplares similares